Research Article

Determination of Senegenin and Tenuifolin in Mouse Blood by Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry and Their Pharmacokinetics

Xiuwei Shen,1 Xiangyi Dai,2 Yifan He,2 Congcong Wen,2 and Qingwei Zhang3

1Ruian People’s Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2Laboratory Animal Center, Wenzhou Medical University, Wenzhou, China
3Shanghai Institute of Pharmaceutical Industry Co., Ltd., Shanghai, China

Correspondence should be addressed to Congcong Wen; bluce494949@wmu.edu.cn and Qingwei Zhang; sipiqingwei@163.com

Received 5 March 2022; Revised 28 March 2022; Accepted 30 March 2022; Published 7 April 2022

Academic Editor: Waleed Alahmad

Copyright © 2022 Xiuwei Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

An ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the determination of senegenin and tenuifolin in mouse blood was developed. The pharmacokinetics of senegenin and tenuifolin in mice after intravenous (5 mg/kg) and oral (60 mg/kg) administration were studied, and the absolute bioavailability was calculated. A CORTECS T3 column was used, with a column temperature set at 40°C. The mobile phase was acetonitrile and 0.1% formic acid. Gradient elution was adopted, using a flow rate of 0.4 mL/min and an elution time of 4 min. Quantitative analysis was performed using electrospray ionization (ESI) with multiple reaction monitoring (MRM) in negative ion mode. Institute of Cancer Research (ICR) mice were bled from the tail vein after intravenous or oral administration of senegenin and tenuifolin. A UPLC-MS/MS method was established to determine the blood concentrations of each drug in mice, and the noncompartmental model was used to fit the pharmacokinetic parameters. Senegenin and tenuifolin showed a good linear relationship (r > 0.995) within a concentration range of 5–400 ng/mL in mouse blood. The intraday precision was < 12%, the interday precision was < 14%, and the accuracy was 87–109%. The recovery was > 88%, and the matrix effect was 87–94%. The oral bioavailability of senegenin and tenuifolin in mice was 8.7% and 4.0%, respectively. The established UPLC-MS/MS method is suitable for pharmacokinetic studies of senegenin and tenuifolin in mice.

1. Introduction

Senegenin, an active ingredient from the root extract of the Chinese medicine Radix Polygalae, has neuroprotective and neuroreparative effects and is used to treat insomnia, neurasthenia, and dementia [1, 2]. Recently, it has been confirmed that senegenin can alleviate postoperative cognitive dysfunction-related symptoms caused by liver ischemia-reperfusion in rats by increasing the expression of NR2B in the rat hippocampus [3–5]. Tenuifolin is a secondary metabolite of tenuigenin [6]. It has significantly lower hemolytic toxicity than tenuigenin and a strong cholinesterase inhibitory effect, which can inhibit the secretion of β-amyloid; however, its water solubility (0.036 mg/mL) and intestinal absorption are poor, and its bioavailability is low, which greatly limit its clinical applications.

Since the concentration of biological samples used to study the pharmacokinetics of traditional Chinese medicines (TCMs) is often extremely low, high performance liquid chromatography and highly sensitive mass spectrometry are used. Triple quadrupole mass spectrometry can significantly improve the detection sensitivity to quantitatively analyze TCM pharmacokinetics [7–9].

Some literature have reported the determination of senegenin or tenuifolin in raw materials or TCM using high performance liquid chromatography (HPLC) [10–13] and biological samples by liquid chromatography-tandem mass spectrometry (LC-MS/MS) [14–16], respectively; however, the simultaneous detection of senegenin and tenuifolin has not been reported. Compared with traditional HPLC analysis methods, blood sample analysis can be completed in
only 4 min by UPLC-MS/MS with a high sensitivity and requiring only a small sample. In this study, a UPLC-MS/MS method was established to study the pharmacokinetics of senegenin and tenuifolin in mice.

2. Materials and Methods

2.1. Reagents and Animals. Senegenin (purity >98%, Figure 1(a)), tenuifolin (purity >98%, Figure 1(b)), and saikosaponin B2 (internal standard, purity >98%, Figure 1(c)) were purchased from Chengdu Munster Pharmaceutical Co., Ltd. (Chengdu, China). Chromatographically pure acetonitrile and methanol were purchased from Merck Ltd. (Darmstadt, Germany). Ultrapure water was prepared by a Millipore Milli-Q purification system (Bedford, MA, USA). Institute of Cancer Research (ICR) mice (weight 20–22 g) were purchased from the Animal Experiment Center of Wenzhou Medical University (Wenzhou, China).

2.2. UPLC-MS/MS Condition. Acquity I-Class ultra-performance liquid chromatography and XEVO TQS-micro triple quadrupole mass spectrometer (Waters Corp., Milford, MA, USA) were used. Masslynx 4.1 software was used for data acquisition and instrument control.

A CORTECS T3 column (2.1 mm × 50 mm, 1.6 μm) was used, and its temperature was set to 40°C. The mobile phase consisted of acetonitrile and 0.1% formic acid, with a gradient elution program: 0–0.2 min, acetonitrile 10%; 0.2–1.0 min, acetonitrile 10–70%; 1.0–2.5 min, acetonitrile 70–90%; 2.5–2.8 min, acetonitrile 90–10%; 2.8–4.0 min, and acetonitrile 10%. The flow rate was set to 0.4 mL/min, and the elution time was 4 min.

Nitrogen was used as the desolvation gas (900 L/h) and cone gas (50 L/h). The capillary voltage was set to 2.0 kV, the ion source temperature was 150°C, and the desolvation temperature was 500°C. ESI-MS in negative mode MRM was used for quantitative analysis: senegenin m/z 679.4 > 455.4 (cone voltage 40 V, collision voltage 26 V), tenuifolin m/z 535.3 > 481.3 (cone voltage 36 V, collision voltage 30 V), and internal standard ion m/z 825.4 > 617.5 (cone voltage 20 V, collision voltage 40 V).

2.3. Preparation of Reference Solution. Stock solutions of senegenin (1.0 mg/mL), tenuifolin (1.0 mg/mL), and saikosaponin B2 (0.1 mg/mL) were prepared in methanol-water (50:50). A series of working solutions were prepared by diluting the stock solutions of senegenin and tenuifolin with methanol. The saikosaponin B2 stock solution was diluted with 5% trichloroacetic acid-methanol solution to prepare a solution containing the internal standard saikosaponin B2 with a concentration of 100 ng/mL. All solutions were stored at 4°C.

2.4. Preparation of Standard Curve. Appropriate working solutions of senegenin and tenuifolin were added into blank mouse blood to prepare the standard curves of senegenin and tenuifolin (5, 20, 100, 500, 1000, 2000, and 4000 ng/mL).

The standard curve concentration range was 5–4000 ng/mL.

In the same manner as the standard curve, quality control (QC) samples at three blood concentrations of 10 ng/mL, 450 ng/mL, and 3500 ng/mL were prepared.

2.5. Sample Processing. Blood sample (20 μL) was added to a 1.5 mL Eppendorf tube, and 100 μL of 5% trichloroacetic acid-methanol solution (containing 100 ng/mL of the internal standard saikosaponin B2) was added, vortexed for 1.0 min at 4°C, and then centrifuged at 13,000 r/min for 10 min. The supernatant (80 μL) was taken into the liner tube of the injection bottle, and 3 μL was injected into the UPLC-MS/MS system.

2.6. Pharmacokinetics. Twelve mice were randomly divided into two groups, with six mice in each group: one group was administered intravenously (5 mg/kg) and the other group was administered orally (60 mg/kg). After 0.0833 h, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, and 12 h, 20 μL of blood was collected from the tail vein of mice after intravenous or oral administration of senegenin and tenuifolin, respectively. The samples were stored frozen at −20°C in 1.5 mL Eppendorf tubes. The blood concentration data of mice in each group at different times were substituted into Drug and Statistics (DAS) 2.0 software (China Pharmaceutical University), and the pharmacokinetic parameters were fitted using a non-compartmental model.

3. Results

3.1. Selectivity. Figure 2 shows that the retention times of senegenin, tenuifolin, and internal standard were 1.74 min, 2.05 min, and 1.84 min, respectively. No obvious impurities or endogenous substances interfered with the detection, indicating that the method has good selectivity.

3.2. Linear. A series of standard solutions of different concentrations were prepared as working solutions, and the standard concentration range was 5–4000 ng/mL. Under the same conditions as the blood samples, each peak area was measured, and the ratio of the peak area of the sample and internal standard was used to draw a standard curve. The linearity of the data was evaluated by the standard curve. The standard curve equation of senegenin in mouse blood was $y = 0.00025x + 0.00015$ and $r = 0.9985$. The standard curve equation of tenuifolin was $y = 0.000068x + 0.000053$ and $r = 0.9964$. Among them, $y$ represents the peak area ratio of senegenin and tenuifolin to the internal standard, and $x$ represents the concentration of senegenin or tenuifolin in blood. The lower limit of quantification of senegenin and tenuifolin in mouse blood was 5 ng/mL.

3.3. Precision, Accuracy, Recovery, and Matrix Effects. The precision and accuracy were assessed by six replicate measurements of blood samples for these three QC sample concentration levels. Precision was expressed as the relative standard deviation (RSD), and the intraday and interday...
Precisions were determined by measuring QC samples for three consecutive days. The intraday and interday accuracies of the QC samples were determined by measuring how well the mean of the QC samples matched the true value over three consecutive days. In mouse blood, intraday precision was <12%, interday precision was <14%, accuracy was 87–109%, recovery was >88%, and the matrix effect was 87–94% (Table 1).

3.4. Stability. The accuracy of detecting senegenin and tenuifolin in mouse blood at room temperature for 2 h, −20°C for 30 d, and freeze-thaw stability tests was within the range of 88–109%, and the RSD was within 12% (Table 2). This indicates that senegenin and tenuifolin have good stability in mouse blood samples.

3.5. Pharmacokinetics. Figure 3 shows the drug concentration-time curves obtained from the pharmacokinetic data of senegenin and tenuifolin after intravenous or oral administration in mice. Noncompartmental models were used to fit the main pharmacokinetic parameters (Table 3). The half-lives of senegenin and tenuifolin in mice were relatively short, indicating they were rapidly metabolized. The oral bioavailability of senegenin and tenuifolin in mice was 8.7% and 4.0%, respectively, indicating a low oral bioavailability.

4. Discussion

The application of LC-MS/MS technology to pharmacokinetics research is a very important step in the history of pharmacokinetics development [17]. The sensitivity and specificity of effective substance detection in biological samples have been greatly improved. In the past, due to insufficient economic, scientific, and technological conditions, HPLC was typically used for detection, but its sensitivity and specificity were insufficient. There are many active ingredients that cannot be detected at a certain concentration, so it is difficult to accurately express dynamic changes in the absorption, distribution, metabolism, and excretion of active pharmaceutical ingredients in vivo. LC-MS/MS is characterized by a high detection sensitivity, and the samples can display a good response signal in LC-MS/MS, even at low concentrations [18–20]. The specified precursor ion and product ion transition pair can be monitored, resulting in high specificity [21, 22].
ESI negative ion and positive ion modes are often used in methodological research. Comparing the positive and negative modes, ESI negative ion has higher sensitivity for detecting senegenin and tenuifolin. When using optimized liquid chromatography conditions, the column and mobile phase are decisive. In this experiment, we tried different chromatographic columns such as BEHC18 and CORTECS T3 with different mobile phase compositions and found that CORTECS T3 (2.1 mm × 50 mm, 1.6 μm) and a mobile phase of acetonitrile-0.1% formic acid had appropriate peaks.

Different precipitation solvents, methanol, acetonitrile, methanol-acetonitrile (1:1), methanol-acetonitrile (1:9), 5% trichloroacetic acid in methanol, and 5% trichloroacetic acid in water were screened during sample processing. The recovery of 5% trichloroacetic acid-methanol was the highest, so it was selected as the protein precipitant.

Lin et al. developed a rapid and specific LC-MS/MS method for the simultaneous determination of polylactic acid, senegenin, and 3,6′-dinaphthylsucrose (DSS) in rat plasma, which took 17 min per sample [14]. Lin’s method was applied to the pharmacokinetic studies of polygallic acid, senegenin, and DSS. The half-life $t_{1/2}$ of senegenin was 12.66 ± 5.29 h, and the mean $C_{\text{max}}$ was 89.35 ± 36.3 ng/mL. These were different from half-life $t_{1/2}$ of senegenin.
2.6 ± 0.6 h in this work, which may be affected by mixing with different compounds and the different pharmacokinetics of mice and rats. Ma et al. established and validated a sensitive, reliable, and accurate LC-MS/MS method in negative ion mode for the quantification of tenuifolin in rat plasma and tissue, and

### Table 1: Accuracy, precision, matrix effect, and recovery of senegenin and tenuifolin in mouse blood.

| Compound | Concentration (ng/mL) | Accuracy (%) | Precision (RSD%) | Matrix effect (%) | Recovery (%) |
|----------|-----------------------|--------------|------------------|------------------|--------------|
|          |                       | Intraday     | Interday         | Intraday         | Interday     |
| Senegenin| 5                     | 108.8        | 91.3             | 11.1             | 11.5         |
|          | 10                    | 104.6        | 102.0            | 10.8             | 6.6          |
|          | 450                   | 102.8        | 96.4             | 6.7              | 11.3         |
|          | 3500                  | 96.1         | 103.7            | 6.7              | 10.9         |
|          | 5                     | 109.5        | 87.0             | 11.7             | 13.8         |
| Tenuifolin| 10                   | 96.7         | 107.4            | 5.4              | 12.4         |
|          | 450                   | 108.0        | 89.1             | 9.8              | 9.0          |
|          | 3500                  | 93.5         | 106.3            | 10.5             | 12.0         |

### Table 2: Stability of senegenin and tenuifolin in mouse blood.

| Compound | Concentration (ng/mL) | Autosampler (4°C, 12 h) | Ambient (2 h) | −20°C (30 d) | Freeze-thaw |
|----------|-----------------------|-------------------------|---------------|--------------|-------------|
|          |                       | Accuracy | RSD | Accuracy | RSD | Accuracy | RSD | Accuracy | RSD |
| Senegenin| 10                    | 98.0     | 3.6 | 98.5     | 3.4 | 93.1     | 10.3 | 88.7     | 11.9 |
|          | 450                   | 100.6    | 7.3 | 107.7    | 8.3 | 106.6    | 10.0 | 106.2    | 11.5 |
|          | 3500                  | 102.2    | 3.0 | 97.9     | 1.5 | 103.8    | 8.0  | 99.3     | 8.1  |
| Tenuifolin| 10                   | 101.8    | 3.3 | 99.5     | 4.1 | 108.3    | 11.3 | 90.0     | 11.4 |
|          | 450                   | 102.6    | 6.8 | 103.8    | 2.6 | 94.6     | 3.7  | 104.7    | 4.4  |
|          | 3500                  | 97.8     | 2.5 | 98.5     | 5.0 | 104.1    | 10.4 | 90.3     | 10.4 |

### Table 3: The main pharmacokinetic parameters of senegenin and tenuifolin after intravenous (iv) and oral (po) administration in mice.

| Compound | Group | AUC₀₋₅ (ng/mL·h) | AUC₀₋∞ (ng/mL·h) | t₁/₂ (h) | CLz/F (L/h/kg) | Vz/F (L/kg) | Cmax (ng/mL) |
|----------|-------|------------------|------------------|----------|----------------|-------------|--------------|
| Senegenin| PO, 60 mg/kg | 434.2 ± 67.8 | 454.7 ± 66.0 | 2.6 ± 0.6 | 134.3 ± 21.8 | 503.0 ± 152.0 | 119.7 ± 30.8 |
|          | IV, 5 mg/kg  | 994.3 ± 116.0 | 998.0 ± 116.5 | 1.6 ± 0.4 | 51.1 ± 0.7   | 12.2 ± 4.1  | 1910.6 ± 279.2 |
| Tenuifolin| PO, 60 mg/kg | 170.8 ± 20.8 | 176.1 ± 21.2 | 1.1 ± 0.2 | 343.8 ± 38.7 | 554.7 ± 23.3 | 98.3 ± 19.0 |
|          | IV, 5 mg/kg  | 845.4 ± 171.2 | 849.4 ± 172.6 | 0.8 ± 0.2 | 61.1 ± 1.4   | 7.2 ± 2.2   | 1497.3 ± 351.2 |

![Figure 3: The blood concentration-time curves after intravenous (iv, 5 mg/kg) and oral (po, 60 mg/kg) administration of senegenin (a) and tenuifolin (b) in mice.](image-url)
metabolized in mice, and their oral bioavailability was low. Pharmacokinetic studies showed that the absolute bioavailability was low (0.83 ± 0.28%) when the systemic malabsorption rats were administered orally to observe circulation. Wang et al. developed a sensitive LC-MS/MS method for the simultaneous determination of the three main active components of Polygala saponin hydrolysates in rats, 3,4,5-trimethoxy-cinnamyl acid (TMCA), p-methoxycinnamyl acid (PMCA), and tenuifolin (TF), which required 6 min per sample analysis [16]. Pharmacokinetic studies have shown that TMCA, PMCA, and tenuifolin can be rapidly absorbed into blood, reaching peak concentrations at around 9.1, 9.0, and 24.0 min, respectively. The oral bioavailability of tenuifolin (2.0%) was lower than that of TMCA (90.1%) and PMCA (96.5%), but its residence time in the body (t1/2, 4.8 h, oral dose) was longer than that of TMCA (0.6 h) and PMCA (0.9 h). In this study, the t1/2 of tenuifolin was 1.1 ± 0.2 h, and its bioavailability was 4.0%, which were different from the previous report.

In this experiment, a UPLC-MS/MS method was established, in which multiple reaction monitoring and ESI negative ion mode were used to determine the plasma concentrations of senegenin and tenuifolin in mice. The noncompartmental model was used to fit the pharmacokinetic parameters, and the bioavailability was calculated. The analysis showed that senegenin and tenuifolin were rapidly metabolized in mice, and their oral bioavailability was low.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Authors’ Contributions

Xiuwei Shen and Xiangyi Dai contributed equally to this work.

Acknowledgments

This work was supported by the Young Talent Project of Wenzhou Medical University.

References

[1] H. Li, S. Lin, T. Qin, H. Li, Z. Ma, and S. Ma, “Senegenin exerts anti-depression effect in mice induced by chronic unpredictable mild stress via inhibition of NF-xB regulating NLRP3 signal pathway,” International Immunopharmacology, vol. 53, pp. 24–32, 2017.

[2] R. Jesky and H. Chen, “The neurotogenic and neuroprotective potential of senegenin against Aβ-induced neurotoxicity in PC 12 cells,” BMC Complementary and Alternative Medicine, vol. 16, no. 1, p. 26, 2016.

[3] W. Xie, Y. Yang, X. Gu et al., “Senegenin attenuates hepatic ischemia-reperfusion induced cognitive dysfunction by increasing hippocampal NR2B expression in rats,” PLoS One, vol. 7, no. 9, Article ID e45575, 2012.

[4] T. Pi, X.-W. Zhou, L. Cai et al., “PI3K/Akt signaling pathway is involved in the neuroprotective effect of senegenin,” Molecular Medicine Reports, vol. 13, no. 2, pp. 1257–1262, 2016.

[5] L. Yu, L. Sun, and S. Chen, “Protective effect of senegenin on splenectomy-induced postoperative cognitive dysfunction in elderly rats,” Experimental and Therapeutic Medicine, vol. 7, no. 4, pp. 821–826, 2014.

[6] J. Lv, H. Jia, Y. Jiang et al., “Tenuifolin, an extract derived from tenuigenin, inhibits amyloid-beta secretion in vitro,” Acta Physiologica, vol. 196, no. 4, pp. 419–425, 2009.

[7] Y. Song, K. Wang, X. Wei, T. Wei, T. Xiao, and M. Wei, “Pharmacokinetics, tissue distribution and plasma protein binding rate of palmatine following intragastric and intravenous administration in rats using liquid chromatography tandem mass spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, vol. 203, Article ID 114226, 2021.

[8] X. Sun, X. Liu, and S. Chen,”The pharmacokinetics, tissue distribution, metabolism, and excretion of pinostrobin in rats: ultra-high-performance liquid chromatography coupled with linear trap quadrupole orbitrap mass spectrometry studies,” Frontiers in Pharmacology, vol. 11, Article ID 574638, 2020.

[9] J. J. Liu, Y. Cheng, Y. Y. Shao et al., “Comparative pharmacokinetics and metabolites study of seven major bioactive components of shaoyao-gancao decoction in normal and polycystic ovary syndrome rats by ultra high pressure liquid chromatography with tandem mass spectrometry,” Journal of Separation Science, vol. 42, no. 15, pp. 2534–2549, 2019.

[10] Y. H. Zhang, L. Bai, Z. Y. Li, F. S. Zhang, and X. M. Qin, “HPLC fingerprint and active components determination of polygala tenuifolia root bark and root,” Zhong Yao Cai, vol. 38, no. 7, pp. 1408–1412, 2015.

[11] X. B. Dong, J. Li, Y. Jiang et al., “Determination of tenuifolin in tianwang buxinwan and guipiwan by HPLC,” Zhongguo Zhongyao Zazhi, vol. 32, no. 16, pp. 1647–1649, 2007.

[12] H. Yan, Z.-D. Zheng, H.-F. Wu, X.-C. Liu, and A. Zhou, “A microemulsion high-performance liquid chromatography (MELC) method for the separation and determination of hydrolyzed tenuifolin in Radix Polygalaes,” Scientific Reports, vol. 9, no. 1, Article ID 19108, 2019.

[13] D. D. Wang, L. Bai, X. S. Xu et al., “Rationality of commodity criteria and traditional breeding of Polygala tenuifolia based on agronomic traits and determination of chemical components,” Zhongguo Zhongyao Zazhi, vol. 41, no. 20, pp. 3733–3740, 2016.

[14] L. Lin, L. Yan, H. Zhang et al., “Simultaneous analysis of polygala acid, senegenin and 3,6′-disinapoylsucrose in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study after oral administration,” Biomedical Chromatography, vol. 28, no. 5, pp. 594–600, 2014.

[15] B. Ma, X. Li, J. Li et al., “Quantitative analysis of tenuifolin concentrations in rat plasma and tissue using LCMS/MS: application to pharmacokinetic and tissue distribution study,” Journal of Pharmaceutical and Biomedical Analysis, vol. 88, pp. 191–200, 2014.

[16] Q. Wang, B.-X. Xiao, R.-L. Pan et al., “An LC-MS/MS method for simultaneous determination of three polygala saponin hydrolysates in rat plasma and its application to a pharmacokinetic study,” Journal of Ethnopharmacology, vol. 169, pp. 401–406, 2015.
[17] Y. Wang, L. Zhang, S. Gu et al., “The current application of LC-MS/MS in pharmacokinetics of traditional Chinese medicines (recent three years): a systematic review,” Current Drug Metabolism, vol. 21, no. 12, pp. 969–978, 2020.

[18] B. X. Weng, Z. Q. Zhong, Y. Yu, J. Lin, and C. C. Wen, “Determination and pharmacokinetics of cepharanthine in rat plasma by UPLC-MS/MS,” Latin American Journal of Pharmacy, vol. 39, no. 6, pp. 1100–1104, 2020.

[19] K. Ren, H. Shi, F. Hong, Y. H. Yu, W. C. Ma, and J. S. Ma, “Pharmacokinetic study of hirsuteine in mice after intravenous administration by UPLC-MS/MS,” Latin American Journal of Pharmacy, vol. 39, no. 9, pp. 1875–1879, 2020.

[20] E. J. Qiu, H. Z. Wang, Y. Yu, D. Z. Song, J. Z. Cai, and F. F. Ye, “Determination of delteline in rat plasma by UPLC-MS/MS and its application to pharmacokinetics,” Latin American Journal of Pharmacy, vol. 39, no. 6, pp. 1171–1175, 2020.

[21] E. Zhang, Y. Wang, F. Xie, X. Zhuang, X. Wang, and X. Yu, “Development and validation of a UPLC-MS/MS method for the quantitative determination and pharmacokinetic analysis of cirsimarin in rat plasma,” BioMed Research International, vol. 2021, Article ID 9953664, 7 pages, 2021.

[22] J. Yang, G. Zeng, J. Ma, X. Wang, and Q. Zhou, “Pharmacokinetics of 10-hydroxy mesaconitine in rat plasma by ultra-performance liquid chromatography-tandem quadrupole mass spectrometry,” Journal of Analytical Methods in Chemistry, vol. 2021, Article ID 6640184, 6 pages, 2021.